12/28/2023 0 Comments Regeneron checkmate![]() Vidutolimod is administered into the tumor and is believed to induce and expand anti-tumor T cells and induce tumor regression as a monotherapy in patients whose tumors previously progressed on PD-1 checkpoint inhibition. Vidutolimod is currently being studied in combination with other agents for melanoma, non-melanoma skin cancers, and head and neck cancer. ![]() The transaction is expected to close in mid-2022.Ĭheckmate's lead investigational candidate is vidutolimod, an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 or TLR9 agonist delivered in a virus-like particle. a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to. ![]() Upon the successful completion of the tender offer, Regeneron will acquire all remaining shares through a second-step merger. The closing of the tender offer will be subject to certain conditions, including the tender of at least a majority of shares, the expiration of the waiting period and other customary closing conditions. Through a subsidiary, Regeneron plans to launch a tender offer to acquire all outstanding shares of Checkmate for 10.50 a share, all cashmore than quadruple that company’s closing share price yesterday of 2.41, down 5 from 2.54 on Friday. Under the deal, Regeneron, through a subsidiary, will initiate a tender offer to acquire Checkmate shares. ![]() The proposed acquisition values Checkmate, a clinical stage biopharmaceutical company focused on cancer, at a total equity value of approximately $250 million. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |